On September 10, 2024, Hebo Pharmaceutical Holdings Limited (Hebo Pharma-B) submitted a next-day disclosure report to the Hong Kong Stock Exchange, disclosing changes in its shareholding. The report shows that as of August 31, 2024, Hebo Pharma had 768,876,410 issued shares. On September 10, 2024, the company repurchased 31,000 ordinary shares at a repurchase price ranging from HKD 1.11 to HKD 1.12, for a total payment of HKD 34,680. After the repurchase, the company's issued shares decreased to 768,845,410 shares, while treasury shares increased to 31,000 shares. The share repurchase has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. According to the rules, the company is not allowed to issue new shares or sell or transfer any treasury shares within 30 days after the share repurchase, unless approved by the exchange.

On September 10, 2024, Hebo Pharmaceutical Holdings Limited (Hebo Pharma-B) submitted a next-day disclosure report to the Hong Kong Stock Exchange, disclosing changes in its shareholding. The report shows that as of August 31, 2024, Hebo Pharma had 768,876,410 issued shares. On September 10, 2024, the company repurchased 31,000 ordinary shares at a repurchase price ranging from HKD 1.11 to HKD 1.12, for a total payment of HKD 34,680. After the repurchase, the company's issued shares decreased to 768,845,410 shares, while treasury shares increased to 31,000 shares. The share repurchase has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. According to the rules, the company is not allowed to issue new shares or sell or transfer any treasury shares within 30 days after the share repurchase, unless approved by the exchange.